According to related industries, the Ministry of Food and Drug Safety is in the process of final review for approval of Imjudo, a CTLA-4 inhibitor. Final approval is expected in the second half of the year. The first indication for Imfinzi and Imjudo combination therapy is liver cancer. The combination therapy is the only dual immunotherapy that has been approved for the first-line treatment of liver cancer and was approved by the US FDA in October last year as a treatment for unresectable hepatocellular carcinoma. In addition, it obtained marketing approval from Japan's Ministry of Health, Labor and Welfare in December last year and EMA in Europe in February.

The combination therapy is a STRIDE (Singl